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Abstract: In breast cancer it is never the primary tumour that is fatal; instead it is the 
development of metastatic disease which is the major cause of cancer related mortality. 
There is accumulating evidence that suggests that Cancer Stem Cells (CSC) may play a 
role in breast cancer development and progression. Breast cancer stem cell populations, 
including  side  population  cells  (SP),  have  been  shown  to  be  primitive  stem  cell-like 
populations,  being  long-lived,  self-renewing  and  highly  proliferative.  SP  cells  are 
identified using dual wavelength flow cytometry combined with Hoechst 33342 dye efflux, 
this ability is due to expression of one or more members of the ABC transporter family. 
They have increased resistance to chemotherapeutic agents and apoptotic stimuli and have 
increased  migratory  potential  above  that  of  the  bulk  tumour  cells  making  them  strong 
candidates  for  the  metastatic  spread  of  breast  cancer.  Treatment  of  nearly  all  cancers 
usually involves one first-line agent known to be a substrate of an ABC transporter thereby 
increasing the risk of developing drug resistant tumours. At present there is no marker 
available to identify SP cells using immunohistochemistry on breast cancer patient samples. 
If SP cells do play a role in breast cancer progression/Metastatic Breast Cancer (MBC), 
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combining chemotherapy with ABC inhibitors may be able to destroy both the cells making 
up the bulk tumour and the cancer stem cell population thus preventing the risk of drug 
resistant disease, recurrence or metastasis. 
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1. Introduction 
In breast cancer the primary tumour is never the cause of death; the development of metastatic disease 
is the major cause of cancer related mortality [1]. In the UK, breast cancer survival rates have improved 
greatly over the last few decades with a 5-year relative survival rate of 82% between 2001 and 2006 [2]. 
However this rate is reduced dramatically with the onset of metastatic disease, with a 5-year survival rate 
of only 12.98% recorded in 2002 for breast cancer patients with stage IV breast cancer [2]. 
Metastatic  breast  cancer  (MBC)  and  its  causes  therefore  remains  a  major  concern  with 
approximately 30% of patients with early stage breast cancer eventually progressing to metastatic 
disease [3]. Currently there is no standardised treatment for MBC. First-line treatment often involves 
the use of an anthracycline and/or taxane with or without endocrine treatment, and while results with 
these agents may be initially encouraging, frequently disease progression occurs within 6–10 months [3]. 
It is thought that the development of chemotherapy resistance can be attributed to treatment failure in 
over 90% of MBC patients [3]. If progression occurs or the patient is resistant to anthracycline/taxanes 
they can be offered capecitabine, gemcitabine, vinorelbine or albumin-bound paclitaxel with average 
response rates of 20–30% [3]. Unfortunately, these second-line agents offer little or no benefit to long 
term patient outcome [3]. 
Cancer develops through the progressive accumulation of genetic mutations that transforms normal 
cells  into  a  malignant  phenotype.  Carcinogenesis  results  in  cells  acquiring  more  primitive  cell 
characteristics, such as the ability to self-renew and an infinite capacity to divide [4,5], which can 
occur as a result of mutations affecting self-renewal, cell survival, proliferation and apoptosis [6,7]. 
There are two main hypotheses on the origin of cancer: 
1.  Stochastic theory; 
2.  Hierarchy (Cancer Stem Cell) theory. 
The stochastic theory predicts that every cell within a tumour can generate a new tumour when in 
the correct microenvironment [6]. However, the probability of these cells entering the cell cycle is low [8]. 
This would suggest that tumours are relatively homogeneous in nature. Evidence to support this theory 
is that cancer cells within the same tumour tend to express a variation of markers representative of 
normal cellular differentiation [9]. Studies have also shown that mouse fibroblasts can be induced to 
form pluripotent stem cells [10] and mature rat hepatocytes can form small hepatocyte-like progenitor 
cells which can regenerate the liver after retrorsine injury [11]. However, primordial germ cells, which 
form teratocarcinomas were found to be no more differentiated than there malignant counterparts [4,8]. 
For example, if cancer is believed to be a result of differentiated cells gaining mutations that increase 
their  life  span,  these  cells  will  not  express  stem  cell  markers.  Also,  these  cells  are  terminally Cancers 2011, 3                         
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differentiated, proliferate for a short period of time and are subject to a high rate of turnover, which 
means that they are unlikely to accumulate enough mutations to undergo neoplastic transformation [12].  
The cancer stem cell (CSC) theory has been attributed to Cohnheim (1875) who postulated that 
stem cells misplaced during embryogenesis may be responsible for tumour formation later in life [13-15]. 
Histological analysis of embryonic and neoplastic tissue and comparison of their growth characteristics 
shows  many  similarities  [16],  for  example  they  are  both  able  to  self-renew,  differentiate,  resist 
damaging agents, are long-lived, able to migrate and have extensive proliferative potential [17,18]. 
Studies  on  teratocarcinomas  show  that  they  are  heterogeneous  tissues  containing  a  variety  of 
undifferentiated and differentiated cell types which is consistent with tissues derived from stem cells. 
Pierce (1974) expanded on Cohnheim‘s theory [15] hypothesising that neoplasms develop from normal 
stem cells which do not escape developmental influences as suggested by Cohnheim but instead develop 
and function normally until carcinogenesis alters intercellular controls regulating their proliferation [19]. 
More recently the CSC model has been referred to as the hierarchy theory which predicts that only a 
small number of cells are capable of initiating a tumour but can do so at a high frequency. This suggests 
that tumours are heterogeneous in nature [5,6,17,20-22]. There are several reasons to believe that stem 
cells may be involved in carcinogenesis, for example there is evidence that most tumours develop over 
months or years which requires the transformational mutations to occur in cells with a long-life span. The 
longevity  of  stem  cells  means  that  they  could  accumulate  enough  mutations  to  undergo  neoplastic 
transformation [13,18,22-24]. Self-renewal ability of stem cells also means that it would require fewer 
mutations to become neoplastic compared to more differentiated cell types [25,26]. 
Over the last few years there has been a surge in the number of studies investigating the role of CSC in 
tumour progression, however most research has focussed on the involvement in the primary tumour. CSC 
are tumour cells that are capable of self-renewal and give rise to heterogeneous tumour masses [13,27,28]. 
They  are  defined  as  ‗cells  that  have  the  ability  to  form  tumours  in  immunodeficient  mice  that 
recapitulate the heterogeneity of the tumour from which they were isolated [27]‘, and thus they share 
many properties with stem cells, being long-lived, self-renewing and highly proliferative. They have 
increased resistance to  chemotherapeutic agents and apoptotic stimuli and have increased  migratory 
potential  above  that  of  the  bulk  of  tumour  cells  [29-34].  The  origin  of  CSC  remains  unclear.  It  is 
unknown if CSC are dedifferentiated cells that have acquired a more stem cell-like phenotype or if they 
are  stem  cells  which  through  longevity  have  accumulated  the  sufficient  number  of  mutational  hits 
required for carcinogenic transformation to occur or if they are due to a combination of both these factors. 
Evidence suggests that conventional chemotherapy targets the bulk of the tumour cells allowing slow 
cycling cells such as CSC to persist after treatment and promote further/metastatic disease [13]. 
2. Metastasis 
In 1889, Paget devised the ―seed and soil hypothesis‖ of cancer metastasis in which he suggested 
that the seeds of cancer (the tumour cells) have an ability to survive in specific soils (organs) that are 
conducive  to  their  growth  [35].  This  hypothesis  could  easily  refer  to  the  properties  of  CSC.  The 
metastatic process is complex, non-random and involves a long series of interrelated steps, any of 
which  may  be  rate-limiting  [36-39].  Metastatic  steps  include:  progressive  growth  of  the  primary 
tumour  which  requires  the  establishment  of  a  good  blood  supply  through  angiogenesis,  in  which Cancers 2011, 3                         
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growth  factors  regulate  the  breakdown  of  the  extracellular  matrix  (ECM)  and  also  cause  the 
proliferation and migration of endothelial cells [37,40]. Cells capable of metastasis also acquire the 
ability to invade [37]. For epithelial cancers this involves cells undergoing an Epithelial-Mesenchymal 
Transition (EMT). EMT involves epithelial cells losing their epithelial characteristics and acquiring a 
more mesenchymal phenotype which occurs as a result of cytoskeletal changes within the cells. These 
changes allow the cell to acquire a more migratory phenotype [36,41], increasing the probability of 
tumour cells entering the blood and lymphatic systems. This process is influenced by chemokines and 
their receptors which are thought to play an important role in tumour development by influencing 
tumour  transformation,  survival,  proliferation,  invasion  and  metastasis  and  also  regulation  of 
angiogenesis and tumour-leukocyte interactions. Despite this, the majority of circulating tumour cells 
appear to be destroyed [37]. Those that persist may acquire the ability to metastasise and once inside 
the  target  organ  may  undergo  Mesenchymal-Epithelial  Transition  (MET),  proliferate  and  if  the 
environment is conducive the disseminated cells may grow to establish a new tumour thus completing 
the metastatic process [38].  
3. Role of Breast Cancer Stem Cells in Metastasis 
There is accumulating evidence which suggests that CSC may play a role in metastasis [42]. Breast 
cancer stem cells can be identified using several methods [43]: 
1.  Mammosphere—Forming ability [44-46]; 
2.  Flow cytometry—Analysis of breast cancer stem cell markers including CD44 [17], CD24 [47,48], 
CD49f  [49-51]  and  aldehyde  dehydrogenase  1  (ALDH1)  [52].  Cells  are  then  sorted  and 
characterised  further  using  clonogenicity,  proliferation,  differentiation  and  in  vivo 
tumourigenicity assays; 
3.  Label retention studies—For example radioactive thymidine and BrdU [53-55]; 
4.  Quiescence—Pece and colleagues (2010) have isolated normal human mammary stem cells 
using the lipophilic dye, PKH26 which is retained by quiescent cells [56]; 
5.  Functional  assays—Side  Population  (SP)  cells  which  have  an  increased  ability  to  efflux 
Hoechst 33342 dye [57] and ALDH-positive cells that are identified using the Aldefluor assay 
which identifies cells with high aldehyde dehydrogenase activity [52,58]; 
The use of cell surface markers to identify CSC from solid tumours requires careful optimisation of 
antibodies and the gated populations must be validated using both in vitro and in vivo functional assays. 
Discrepancies in marker expression may arise due to the manipulations required to prepare the samples 
for analysis, for example tumour dissociation into single cell suspensions and culturing of cells may 
alter cell behaviour and viability. Unlike normal tissue stem cells, CSC are influenced by the specific 
genetic aberrations of the tumour, by the stage of the disease and also by any therapeutic interventions 
given to the patient [59]. In patient tumours, CSCs are ‗moving targets‘ (cells that are continually 
evolving) making it difficult to isolate these cells in the clinic. The clinician needs to be able to 
identify the different CSC populations in the patient throughout all stages of disease progression and 
needs  to  be  able  to  target  this  population  without  detrimental  effects  on  the  normal  stem  cell 
populations [27,59]. Cancers 2011, 3                         
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At present most of what we know about the role of CSC in breast cancer metastasis has been based 
on ALDH-positive, CD133-positive or CD44
+CD24
−/low breast CSC populations [58,60-62]. Breast 
cancer is a heterogeneous disease which can be classified into different subtypes based on histology or 
molecular profiling [63,64]. It is becoming apparent that different breast cancer subtypes may result 
from different breast cancer cell populations. ALDH has been used to identify hematopoietic stem cells 
(HSC) in both mice and humans [52,65-67], normal mammary stem cells, and also CSC populations in 
AML  [68],  multiple  myeloma  [67,69],  and  malignant  human  mammary  epithelial  cell  lines  [52].  
In xenograft human breast tumours, these cell types displayed cancer stem cell properties giving rise to 
tumours in vivo that recapitulated the heterogeneity of the tumour from which they were isolated [52]. 
ALDH
+ cells have been shown to mediate invasion and metastasis in inflammatory breast cancer [70] 
and this population is increased in basal breast cancer cell lines and in breast tumours from patients 
following  neoadjuvant  chemotherapy  [71].  In  fact,  ALDH1  has  been  found  to  be  an  independent 
predictive factor for early metastasis and decreased survival in patients [70]. Marcato and co-workers 
assessed the expression of 19 ALDH isoforms and demonstrated that CSC in breast tumours could be 
identified using the ALDH1A3 isoform and it was shown that the expression of ALDH1A3 correlated 
with breast tumour grade and stage and correlated prevalence of CSC with metastatic breast cancer [72]. 
Independently, both CD44
+ [73,74] and CD24
+ [47,75] breast cancer cell populations have been 
shown to be involved in the metastatic process. Data on the role of CD44
+ or CD24
− cells in metastatic 
tissues  is  conflicting,  Shipitsin  and  co-workers  determined  that  the  CD24
+  cell  population  was 
increased in distant metastases regardless of the site of metastases [74]. However, no correlation was 
observed when comparing CD44
+ cells in primary invasive tumours and matched samples taken from 
metastatic sites [74]. CD44 is subject to extensive alternative splicing and different splice variants of 
CD44 have been shown to be involved in metastasis in a variety of different cancers and have been 
associated with poor patient outcome [76]. For example CD44v3, CD44v6 and CD44v7/8 variants 
have been shown to correlate with more aggressive breast cancer subtypes [76]. Brown and colleagues 
have demonstrated that it is essential for a switch in CD44 expression from CD44 variants (CD44v) to 
CD44 standard isoform (CD44s) for Epithelial-Mesenchymal Transition (EMT) to occur in vivo [77]. 
In  2003,  Al-Hajj  and  colleagues  identified  a  population  of  cells  in  human  breast  cancers  with  a 
Lin
−ESA
+CD44
+CD24
−/low  phenotype  that  were  highly  tumourigenic  in  vivo  and  were  the  only  cell 
population capable of forming tumours in NOD/SCID mice that recapitulated the heterogeneity of the 
tumour from which they were isolated [17]. Sheridan and co-workers (2006) discovered CD44
+CD24
−/low 
populations constituted a high proportion of the total cell population in basal or myoepithelial breast 
cancer cell lines [47]. These cell lines expressed high levels of the proinvasive genes Il-1α, Il-6 and Il-8 
and  were  more  invasive  than  cell  lines  containing  less  than  30%  CD44
+CD24
−/low  cells  [47]. 
Subsequently, studies have shown that CD44
+CD24
−/low cells are slow cycling, chemoresistant, capable 
of forming mammospheres and are enriched in drug resistant cell lines [78,79].  
Studies correlating the presence of CD44
+CD24
−/low cells in breast tumours with patient follow up 
have produced conflicting data. Abraham and colleagues determined that 78% of breast cancer cases 
assessed  contained  a  CD44
+CD24
−/low  population  constituting  less  than  10%  of  the  total  cell  
population [80]. No significant correlation between the prevalence of CD44
+CD24
−/low expressing cells 
and response to different therapeutic regimes was observed [80]. Conversely, Li and co-workers showed 
that the proportion of cells with the CD44
+CD24
−/low phenotype was significantly increased following Cancers 2011, 3                         
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neoadjuvant  chemotherapy  [81].  The  majority  of  studies  investigating  CD44
+CD24
−/low  cells  have 
utilised antibodies that do not discriminate between CD44 isoforms. In the future it would be beneficial 
to investigate expression of specific CD44 isoforms and their affect on the CD44
+CD24
−/low phenotype.
 
In breast cancer, CD133 appears to play less of a role as a stem cell marker than in other cancers [61]. 
However, CD133
+ cells have been identified in breast cancer cell lines created from Brca1-deficient 
murine mammary tumours and these cells were highly tumourigenic, expressed common stem cell 
markers  and  were  resistant  to  DNA-damaging  chemotherapy  [79].  A  population  of  cells  with  a 
CD44
+CD29
hiCD133/2
hi phenotype has also been identified in ERα-negative human breast tumours 
that was highly tumourigenic, capable of self-renewal and also expressed common stem cell markers [82].  
4. Side Population Cells 
Another putative CSC population are Side population (SP) cells. SP cells are identified using dual 
wavelength  flow  cytometry  combined  with  Hoechst  33342  dye  efflux  [57,83].  SP  cells  have  an 
elevated rate of Hoechst efflux which is attributed to the expression of one or more members of the 
ABC transporter family [34,84]. The SP phenotype is a functional ability within this cell population 
and is not reliant on the use of cell surface markers. Many groups are assessing the role of SP cells in 
different cancers however, results need to be analysed cautiously. Hoechst 33342 is a DNA binding 
dye which is toxic to cells at high concentrations and this is exacerbated by exposure to UV light. It is 
important to optimize the Hoechst 33342 dye concentration, the incubation time and cell counting in 
order to minimise cell toxicity [85,86]. Some studies have shown that Hoechst 33342 dye can impair 
cell differentiation [87], clonogenicity [88,89] and tumourigenicity [87,90-92]. Cell viability may also 
be  affected  by  Hoechst  33342  dye  [88]  or  by  the  cell  sorting  process  [89,90]  and  therefore  it  is 
important to perform a functional assessment of cell viability to overcome this issue [86].  
SP cells were first identified in murine bone marrow and were thought to be a stem cell (a cell type 
that  has  the  ability  to  self-renew  and  differentiate  to  give  rise  to  more  restricted  cell  types  [13]) 
population as they expressed the phenotypic markers of multipotent Haematopoietic Stem Cell (HSC; 
Lin
−SCA-1
+), were capable of contributing to both the lymphoid and myeloid cell lineages and were 
highly enriched in HSC activity [57]. SP cells have since been identified in a diverse array of normal 
tissues including, lung, heart, endometrium and mammary gland [93-96]. Several cancer cell lines have 
also been shown to contain an SP population including breast cancer, lung cancer, prostate cancer and 
ovarian cancer cell lines [20,97-99]. SP cells have also been identified in solid tumours including 
mesenchymal  tumours,  breast  tumours,  neuroblastomas  and  ascites  extracted  from  ovarian  cancer 
patients  [20,91,99-101].  SP  have  been  shown  to  possess  stem  cell-like  properties  within  these  
tissues [20,91,93-100]. However in some studies, SP cells have not been shown to have stem-cell 
properties. CSC-like  cells  have  been  shown to  play an  important role in  glioblastoma  multiforme 
(GBM) [102]. Broadley and colleagues found that neurosphere formation enriched for stem cell-like 
activity [102]. GBM SP cells were not enriched in neurospheres, were unable to self-renew and had a 
lower tumourigenic potential than non-SP (NSP) cells [102]. SP cells in adrenocortical tumours did not 
have increased ability to proliferate or self-renew and were not more chemoresistant than the NSP 
population  [103].  In  2006,  Shackleton  and  co-workers  demonstrated  that  a  single  cell  with  a 
Lin
−CD29
hiCD24
+ phenotype could function as a mammary gland stem cell reconstituting an entire Cancers 2011, 3                         
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functional murine mammary gland [48]. SP cells were also identified in the murine mammary gland 
but they did not identify the Lin
−CD29
hiCD24
+ population [48]. 
In haematopoietic cells, the SP phenotype has been defined by the expression of ABCG2 [34,84], 
an ABC half-transporter involved in xenobiotic protection [104] and commonly involved in multidrug 
resistance  [105].  The  importance  of  ABCG2  expression  on  the  SP  phenotype  is  demonstrated  by 
studies on Abcg2 null mice which have been shown to have reduced numbers or fewer detectable SP 
cells than wild-type mice. Haematopoietic cells  from  Abcg2
−/− null mice were  shown to  be  more 
sensitive  to  mitoxantrone,  a  drug  commonly  used  in  chemotherapy  [84].  Incorporating  the  green 
fluorescent  protein  (GFP)  reporter  gene  into  the  Abcg2  locus  in  mice  showed  that  91%  of 
haematopoietic SP cells were found to express the Abcg2/GFP allele supporting the role of ABCG2 in 
the SP phenotype [106]. 
5. Characterisation of SP in the Normal Mammary Gland 
SP cells have been identified in both mouse and human mammary gland tissue [93,107]. Analysis of 
the murine mammary gland of Abcg2/Abcb1a/1b triple knockout mice showed almost complete loss of 
mammary gland SP cells, demonstrating in the murine mammary gland that both ABCG2 and ABCB1 
contribute to the mammary gland SP phenotype [108]. It is interesting to note that higher percentages 
of  SP  cells  have  been  identified  in  hyperplastic  mammary  glands  from  MMTV-Wnt-1  and  
MMTV-ΔN-catenin murine models compared to the wild-type control [109]. This suggests that the 
percentage of SP cells increases during breast cancer development and progression in some breast 
cancer subtypes.  
At present there is a debate whether mammary gland SP cells are stem cells or a more-restricted 
mammary gland progenitor cell population. However, regardless of their status, studies have shown 
that human mammary gland SP cells are able to generate luminal and myoepithelial lineages [93], to 
form branching structures in matrigel and preferentially form spheres in vitro[110,111].  
6. SP cells: A Presence in Numerous Cancers and Cancer Cell Lines 
Patrawala and colleagues (2005) found that 30% of human cancer cells and xenograft tumours contain 
SP cells [98]. Extensive studies have attempted to characterise SP cells isolated from cancer cell lines and 
have identified shared properties between cancer SP cells. SP cells isolated from cancer cell lines have been 
found to be capable of self-renewal [99], can undergo asymmetric division [20,31,97-99,112,113] and 
express common stem cell markers including Notch1 and Bmi1 [20,97,98,114]. In the majority of studies, 
SP  have  also  been  found  to  be  chemoresistant  [20,97,99,112,115],  radioresistant  [114,116]  and  have 
increased invasive potential in vitro [117] compared to NSP cells [97,112,115]. In vivo studies have also 
demonstrated that in most cancer cell lines SP are more tumourigenic [97,99,113-115,118,119] and have 
greater metastatic potential [118,120,121] than their NSP counterparts [122]. 
7. SP in Breast Cancer Cell Lines 
Extensive work has been performed to characterise SP cells in breast cancer cell lines [20,92,98,123-126]. 
Purified SP from the MCF7 breast carcinoma cell line had increased expression of the ‗stemness genes‘ Cancers 2011, 3                         
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Notch1  and  β-catenin  [98],  have  a  large  nuclear-to-cytoplasmic  ratio  compared  to  NSP  cells  
(a  stem  cell  characteristic)  and  breast  cancer  cell  line  SP  populations  are  capable  of  asymmetric 
division in vitro. In contrast, NSP cells could only generate NSP cells in vitro [92,113,123]. In vivo, 
breast cancer SP cells have been shown to be more tumourigenic than NSP cells when transplanted 
into immunodeficient mice [92,98,113,121]. 
The importance of ABC transporters in defining the SP phenotype in normal tissues has led to an 
abundance of studies investigating the role of these transporters in breast cancer SP cells. Many studies 
have reported increased transcriptional expression of ABCG2 in SP compared to NSP cells [92,98,121,123] 
in several breast cancer cell lines, and this has been confirmed at the protein level [113]. Targeting 
ABCG2 with ABCG2 inhibitors or siRNA has been shown to eliminate the SP population in the MCF7 
cell  line  [113].  Studies  have  determined  that  MCF7  SP  are  more  radioresistant  [116]  and 
chemoresistant  to  agents  including  mitoxantrone  and  carboplatin  [92,113,121]  than  the  NSP  cell 
population.  MCF7  SP  cells  have  also  been  shown  to  have  a  CD44
+CD24
−CK18
+EpCAM
+CK19
+ 
phenotype [121,124] and both MCF7 SP and CD44
+CD24
−/low cells are enriched in mammosphere 
formation and both populations are preferentially inhibited by NF-κβ pathway inhibitors compared to 
their non-stem cell  counterparts  [126]. These  properties would suggest  that SP cells may  play an 
important role in breast cancer progression in some breast cancer subtypes. Perhaps the presence of an 
SP population may be indicative of a cohort of patients within a breast cancer subtype that have a 
poorer  response  to  particular  therapeutic  options  and  thus  these  individuals  may  have  a  poorer 
prognosis.  Conversely,  in  other  breast  cancer  subtypes  where  SP  are  not  prevalent  another  breast 
cancer stem cell population may be responsible for poor prognosis/chemotherapeutic resistance. 
There  is  evidence  to  suggest  that  SP  cells  may  undergo  EMT  and  numerous  studies  have 
demonstrated an association between EMT, chemoresistance and stem cells [41,44,127,128]. Inducing 
EMT in the breast cancer cell line MCF7 by the addition of EGFR has been correlated with increased 
invasive potential and an increased resistance to tamoxifen [129]. Also, doxorubicin induced EMT in 
murine 4T1 breast cancer cells has been shown to lead to an enrichment of Sca-1-positive cells with an 
increased invasive potential [130]. SP cells have been shown to be more responsive to TGFβ signalling 
than NSP cells; with TGFβ treatment increasing the invasive potential and inducing EMT in the SP 
population in pancreatic cancer cell lines [31]. Upon removal of TGFβ treatment, pancreatic cancer SP 
cells were also capable of MET [31]. 
Cancer SP cells are known to be chemoresistant and this has been attributed to the expression of 
ABC transporters [20,99,131]. Unlike the study on pancreatic cancer SP cells [31], it has been shown 
that  in  the  MCF7  breast  cancer  cell  line,  TGFβ  induced  EMT  and  depleted  the  SP  population,  
down-regulated ABCG2 gene expression and increased cell sensitivity to mitoxantrone [113]. The 
removal of TGFβ restored the SP phenotype and ABCG2 expression [113]. Knockdown of e-cadherin 
reduced the SP population but did not affect expression of ABCG2 mRNA or protein thus providing 
evidence  that  the  EMT  response  reflects  post-translational  regulation  of  ABCG2  function  by  
e-cadherin as well as transcriptional repression of the ABCG2 gene [113]. These studies need to be 
repeated  using  other  cancer  cell  lines  and  primary  tumour  SP  cells  in  order  to  have  a  better 
understanding of the involvement of SP in EMT. Cancers 2011, 3                         
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8. SP in Breast Tumours 
SP cells have been identified in a diverse array of breast cancer cell lines that are classified within 
different breast cancer subtypes [123]. However, Clarke and co-workers (2005) have identified SP cells 
in normal human breast tissue and showed that these cells were ER-positive [111]. This has resulted in it 
being postulated that SP cells may be predominantly identified in luminal breast tumours [132]. Analysis 
of putative breast cancer stem cell markers in primary breast cancers demonstrated that different breast 
cancer stem cell populations were prevalent in different breast cancer subtypes. Basal-like tumours 
were  found to  contain a  higher proportion of cells  with a  CD44
+CD24
−/low [47] or  ALDH1
+  [52] 
phenotype whilst Her2-positive cancers predominantly contained ALDH1
+ cells. This study did not 
identify a prevalent breast cancer stem cell population in luminal breast tumours. 
To date only Nakanishi and colleagues have identified SP cells in clinical breast tumours which 
were characterised as luminal cancers [100]. The percentage of SP cells was higher in luminal type 
(predominantly  ER
+PR
+Her2
+)  breast  cancer  cell  lines  and  these  cell  lines  had  increased  colony 
forming ability in vitro compared to basal a (CK5
+ and CK14
+) or basal b (vimentin
+) subtypes. A 
strong correlation was observed between Her2 expression and SP presence with the percentage of SP 
increasing in cell lines enforced with expression of Her2. Treatment with the Her2 signalling inhibitors, 
tyrophostin AG825 or trastuzumab, decreased the proportion of SP cells in breast cancer cell lines and 
also  inhibited  tumour  growth  in  vivo  [100].  The  authors  concluded  that  their  data  highlights  the 
important role that Her2 plays in regulating SP cells and could account for the poor chemotherapeutic 
response and aggressive nature of Her2-positive breast cancers [100]. Unfortunately the media used in 
this study selected for primary breast cancer cells that had a luminal nature which means as yet it is 
unknown if SP cells can be identified in other breast cancer subtypes. This highlights the importance of 
identifying SP cells in all patient breast tumour subtypes and relating the presence of these cells to 
patient follow up in order to elucidate the role of SP cells in breast cancer and potentially to highlight 
new therapeutic targets. It may also be beneficial to use the identification of patient SP cells as a tool 
to determine which patients require a more aggressive treatment regime due to increased expression of 
MDR transporters that may be specifically tailored to eradicate this population of cells. 
9. SP and Breast Cancer Metastasis 
As yet there is no published literature investigating the metastatic potential of SP cells in breast 
cancer. However, studies in other cancers have shown that SP cells may play a role in metastatic 
spread of disease [95,120]. Kato and co-workers injected SP and NSP flow cytometrically sorted cells 
from the Hec-1, human endometrial cancer cell line, subcutaneously into immunodeficient mice and 
discovered that tumours derived from SP cells were highly invasive with cells invading through the 
basement  membrane  into  the  spine,  peritoneum,  leg  and  bone  [95].  In  contrast,  NSP  cell  derived 
tumours were encapsulated and clearly separated from the basement membrane of the mouse skin [95]. 
SP  isolated  from  the  pancreatic  cancer  cell  line  PANC-1  have  been  shown  to  have  an  increased 
invasive potential in vitro and increased metastatic potential in vivo when compared to NSP cells using 
a murine liver metastasis model [31]. Nishii and colleagues (2009) have shown SP from gastric cancer 
cell lines have increased expression of several adhesion molecules which resulted in SP having a Cancers 2011, 3                         
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greater potential to form peritoneal metastases [120] and the prevalence of SP cells has been shown to 
significantly increase in hepatocellular carcinoma cell lines in a stepwise manner dependent on the cell 
lines metastatic potential, with the highest percentages observed in the most metastatic cell line [131]. 
In primary mesenchymal neoplasms, the percentage of SP cells has been shown to correlate with the 
tumours grade [91]. However to date the presence/percentage of SP cells in primary neoplasms has not 
been correlated to metastasis. 
10. CXCR4, SP cells and Breast Cancer 
The role of the CXCR4/CXCL12 axis in breast cancer metastasis has been well documented [133-137]. 
Several studies have shown how acquisition of the chemokine receptor CXCR4 by breast cancer cells 
can promote specific, chemotactic recruitment to remote sites such as the bone marrow, lymph nodes, 
liver and lung in response to localised expression of the specific chemokine ligand, CXCL12 [133]. 
These studies tie in with the distinct pattern of tumour dissemination to regional lymph nodes, lung, 
liver and bone marrow known to occur as part of the metastatic spread of breast cancer [133]. Stromal 
cells  in  all  of  these  sites  have  been  shown  to  highly  express  CXCL12  and  were  able  to  induce 
chemotaxis and invasion of breast cancer cells in vitro [133]. Several studies using gene silencing 
strategies to reduce CXCR4 expression have demonstrated that this results in impaired invasion of 
breast cancer cells in vitro and inhibits breast cancer metastasis in vivo [133-136]. Primary human 
breast cancer cells can also respond to CXCL12 [133] and in breast cancer patients, high levels of 
CXCR4 expression have been correlated with lymph node metastasis in invasive ductal carcinoma and 
associated with poor overall survival [137,138]. 
11. SP and CXCR4 
SP cells are known to be capable of migration in response to CXCL12 [139,140]. Cardiac SP cells 
transplanted  into  non-infarct  myocardium  were  shown  to  be  capable  of  migrating  into  damaged 
myocardial tissue. This migration in vitro and in vivo being due to the interaction between CXCR4 and 
CXCL12 [140]. Human bone-marrow derived SP cells have also been shown to be CXCR4-positive 
and capable of migrating in response to CXCL12 in vitro [139]. Perhaps as in the case of pancreatic 
cancer  (where  the  CD133
+CXCR4
+  cell  population  is  responsible  for  metastasis  [30]),  it  is  the 
CXCR4-positive SP population of breast cancer cells that are responsible for breast cancer metastasis.  
12. CSC in Primary and Metastatic Breast Disease 
Current treatment for MBC is limited and has little clinical success [3]. There is a high rate of 
disease  progression  in  MBC  patients  who  initially  respond  to  treatment  with  over  90%  of  MBC 
patients developing drug resistant disease [3]. If the SP phenotype in breast cancer is defined by the 
presence  of  ABC  transporters  this  would  make  them  an  ideal  candidate  for  contributing  to  drug 
resistant  MBC.  If  metastases  are  seeded  from  SP  cells  this  would  result  in  an  abundance  of  
MDR-expressing cells making the tumours highly resistant to therapeutic intervention and therefore 
extremely difficult to eradicate [141].  Cancers 2011, 3                         
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To clarify the role of SP cells in MBC, the identification of SP cells needs to be performed in all 
breast cancer subtypes and their presence related to the tumour characteristics and to patient follow up. 
Breast cancer SP cells need to be isolated from patients and extensively characterised which will 
involve the need to transplant these human cells into animal cancer models to elucidate the potential of 
these cells to contribute to invasion and metastasis. A manuscript published by Michael Clarke‘s group 
described the development of a human-in-mouse breast cancer xenograft model in which the metastatic 
potential of breast cancer stem cells could be determined [142]. This group labelled breast cancer stem 
cells with Luc2-eGFP or Luc2-Tom enabling as few as 10 labelled cells to be visualised in vivo and  
ex vivo [142]. It will be necessary to obtain lymph node and primary tumour samples from patients 
undergoing surgery for breast cancer and to determine the presence of SP within these samples. If SP 
are indeed present in lymph nodes of breast cancer patients it could be indicative of patients likely to 
progress with distant metastatic disease. It is already known that the presence of metastases in axillary 
lymph  nodes  is  associated  with  more  aggressive  breast  cancers  and  poor  disease-free  and  overall 
survival in breast cancer patients [143,144]. A disparate hormone receptor status between primary 
breast tumour tissue and nodal tissue has been observed demonstrating the importance of assessing 
breast cancer stem cells in both primary tumour and lymph node samples [145]. Lu et al. (2010) 
detected higher proportions of CD44-positive cells in primary tumour samples analysed from lymph 
node positive supraglottic carcinoma patients compared to lymph node negative patients thus showing 
the importance of identifying CSC in lymph node samples [146].  
13. Treatment Strategies to Target Cancer Stem Cells, Including SP Cells 
The emerging role of cancer stem cells in breast cancer development and progression has led to 
intense work to identify drugs that target the CSC population of drug resistant cells [60]. The importance 
of finding new therapies to target breast cancer stem cells is highlighted by accumulating evidence 
showing the resistance of cancer stem cells to chemotherapy and radiotherapy. Transcriptional profiling 
has been used to define several breast cancer subtypes that require different therapeutic regimes [147]. 
The heterogeneity of breast cancer stem cell populations in different breast cancer subtypes suggests that 
several  targeted  therapies  may  be  necessary.  It  is  hoped  that  increasing  our  understanding  of  the 
molecular biology of cancer stem cells may identify new therapeutic targets. For example, metaplastic 
breast  cancers  have  been  found  to  display  a  similar  ‗tumourigenic  signature‘  to  that  of  the 
CD44
+CD24
−/low breast cancer stem cell population and MBC have been shown to have aberrant MAPK 
components which potentially could benefit from treatment with MAPK pathway inhibitors [147].  
The majority of studies have focused on targeting the CD44
+ and CD44
+CD24
−/low cell populations, 
culminating most recently in the use of Salinomycin, a highly selective potassium ionophore, as a 
compound that could selectively eliminate the CD44
+CD24
−/low breast cancer stem cell population 
compared  to  treatment  with  paclitaxel  alone  [148].  In  vivo,  Salinomycin  was  able  to  inhibit  the 
formation of tumours in the 4T1 murine breast cancer cell model and also in the ras-transformed 
HMLE model. Salinomycin treatment also prevented metastasis of 4T1 cells in vivo [148,149]. The 
mechanism of action of Salinomycin is the induction of a distinct apoptotic pathway that does not lead 
to  cell  cycle arrest and in  this  way results in massive apoptosis in  cancer cells [117]. Fuchs  and 
colleagues  demonstrated  that  Salinomycin  could  even  activate  apoptosis  in  cells  that  were Cancers 2011, 3                         
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chemotherapy resistant or resistant to apoptosis due to the overexpression of factors such as bcl-2, 
MDR1 or 26S proteasomes with increased proteolytic activity [117]. Perhaps the effect of salinomycin 
on cells overexpressing MDR transporters would mean that it could be used to specifically target 
breast cancer SP cells. 
As the SP cell phenotype is a consequence of the expression of ABC transporters, strategies to 
inhibit these might be worth revisiting. Nearly all cancer chemotherapy involves a first-line agent 
known to be a substrate of an ABC transporter [150], thereby increasing the risk of developing drug 
resistant  tumours.  If  SP  cells  do  play  a  role  in  breast  cancer  progression/MBC,  combining 
chemotherapy with ABC inhibitors may be able to destroy both the cells making up the bulk tumour 
and the cancer stem cell population thus preventing the risk of drug resistant disease, recurrence or 
metastasis [104,141,150]. Results from clinical trials of ABC inhibitors have been disappointing with 
first line ABC transporter inhibitors for example verapamil being too toxic for use in cancer patients. 
Second line agents such as Zosuquidar were more potent and less toxic but demonstrated no additional 
clinical benefit in locally recurrent breast cancer or in MBC patients [151]. However, some of these 
trials  have  shown  limited  benefits,  for  example,  clinical  trials  with  PSC  833  showed  that  it  was 
necessary to reduce the dose of the chemotherapy used compared to conventional chemotherapy, as 
combining  chemotherapy  with  PSC  833  resulted  in  a  pharmacokinetic  interaction  that  altered  the 
metabolism of the chemotherapeutic agent [150], thus achieving a statistically significant improvement 
in relapse-free and overall survival [152]. The trial combining PSC 833 with mitoxantrone, etoposide 
and cytosine arabinoside in AML patients had to terminate early due to toxicity issues [153]. However, 
analysis did show a statistically significant improvement in the complete remission rate of patients and 
a  trend  towards  an  improved  disease-free  survival  within  the  treatment  arm  of  the  study  [154]. 
However,  the  use  of  a  broad-spectrum  ABC  transporter  inhibitor  will  be  unlikely  as  the  3  main 
transporters,  ABCB1,  ABCC1  and  ABCG2,  involved  in  multidrug  resistance  are  from  three 
evolutionary  and  structurally  distinct  ABC  transporter  families  making  it  difficult  to  identify  a 
common target [155]. 
In addition to chemoresistance, ABC transporters also play a role in cell migration, differentiation 
and  protection  against  apoptosis  [156-158].  In  MCF7  breast  cancer  cells,  siRNA  knockdown  of 
ABCB1 has been demonstrated to decrease migration and invasion in vitro [159]. ABCC1 has also 
been seen to be more highly expressed in metastatic lymph nodes compared to the primary tumour of 
patients  with  metastatic  breast  cancer  [159].  Therefore  gene  silencing  strategies  alone  or  in 
combination with the use of chemotherapeutic reagents or anti-CSC drugs might prove more effective 
at targeting CSC in MBC. However, it will be important to determine if the breast cancer stem cell 
population can be targeted without detrimental effects on the normal stem cell populations. 
Nakanishi  and  co-workers  (2010)  identified  SP  in  primary  cells  derived  from  patient  breast  
tumours [100] and we confirm the presence of SP in patient breast tumours through detection of SP 
cells in Fine Needle Aspirate (FNA) samples from palpable breast tumours. Targeting SP cells may 
only be relevant to some breast cancer subtypes, such as luminal tumours [100], whilst other therapies 
may be required for other subtypes shown to be driven by different breast cancer stem cell populations. 
SP cells have been observed in both female [100] and male breast cancer patients (Meeson laboratory 
data, Figure 1). This highlights the presence of CSC in male breast cancer, and raises the question can Cancers 2011, 3                         
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we target CSC in both female and male breast cancer cases using the same strategies? No studies 
looking at the role of CSC in male breast cancer have as yet been reported. 
Figure 1. SP profile for a fine needle aspirate taken from a male breast cancer patient.  
(A). A SP population of 0.6% of the total cell population was observed when cells were 
incubated with 2.5 µ g/mL Hoechst 33342 dye; (B). The efflux of Hoechst dye by the SP 
population was partially inhibited by addition of a combination of 10 µ M FTC and 50 µ M 
verapamil prior to the Hoechst incubation. * Prior to Hoechst staining samples were lysed 
twice with Red Blood Cells (RBC) lysis buffer and propidium iodide was added prior to 
flow cytometry analysis to exclude non-viable cells. 
 
The  importance  of  Her2  in  the  regulation  of  breast  cancer  SP  cells  has  been  demonstrated  by 
Nakanishi  and  colleagues  (2010)  and  SP  cells  have  been  observed  to  be  more  prevalent  in  Her2 
overexpressing breast cancer cell lines and luminal breast tumours [100]. The Her2 gene is amplified 
in approximately 20% of all breast cancer cases and is associated with a more aggressive disease and 
commonly  involves  early  onset  of  metastases  [29,160].  In  fact,  breast  cancer  patients  with  
Her2-positive breast cancer cells in their bone marrow at the time of diagnosis have an increased risk 
of metastatic relapse and overall have a poorer prognosis [29].  
Trastuzumab and Lapatinib are targeted therapies against the Her2 receptor and the Her2 pathway 
and are usually only prescribed to patients with Her2-positive breast tumours [161] and clinical studies 
have  determined  the  benefit  of  giving  patients  neoadjuvant  trastuzumab  or  lapatinib  in  both  
Her2-positive and Her2-negative patients [162,163]. Her2 overexpressing cell lines have increased 
mammosphere forming efficiency (MSFE) and an increased ALDH
+ cell population [164]. Treatment of 
Her2 overexpressing cell lines with Trastuzumab reduced the number of ALDH-positive cells and this 
subsequently resulted in decreased invasive and tumourigenic potential of these cells [164,165]. Perhaps 
the benefit of Her2 inhibitors in both Her2-positive and Her2-negative tumours could be due to the 
interaction of these therapeutic agents with the CSC population or SP cells within these patient tumours.  Cancers 2011, 3                         
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14. Conclusion  
Reported in vitro studies show promising results for therapeutically targeting breast CSC but they 
need to be translated into the clinic [117,148,149]. This may be difficult to achieve without standardised 
methods  of  detecting  and  characterising  these  cell  populations  both  before  and  after  therapy.  The 
knowledge of the particular cancer stem cell properties involved in different breast cancer subtypes may 
identify new therapeutic targets especially for metastatic breast cancers in which treatment options are 
currently  limited  [3,147].  It  is  important  that  the  role  of  breast  cancer  stem  cells  in  metastasis  is 
determined.  If  cancer  stem  cells  could  be  targeted  in  breast  cancer  therapy  the  analysis  of  distant 
metastases for the presence of cancer stem cell populations may be beneficial in the selection of therapy. 
If SP is involved in the metastatic process, therapies to target SP cells will need to be sought in 
order to minimise toxicity effects often experienced by treatment with systemic therapies. If ABC 
inhibitors/modulators are to be of use they need to be highly specific in order to reduce systemic 
effects as ABC transporters play a pivotal role in the blood brain barrier, many tissues and most 
normal stem cells [155], and interfering with this process could have catastrophic outcomes in patients. 
Treatments will have to be carefully tested not only on breast cancer SP cells but also on normal SP/stem 
cell populations to determine the impact they may have on normal body processes [166]. Therapeutic 
agents will also need to be tested in combination with commonly used breast cancer therapeutics as the 
effect of each agent alone may be very different to that observed when used in combination.  
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